The primary objective of this study is to determine the safety of LX3305 in a dose escalation compared with placebo over 12 weeks in subjects with active rheumatoid arthritis (RA).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01417052?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
